Computational analysis of human N-acetylgalactosamine-6-sulfate sulfatase enzyme: an update in genotype–phenotype correlation for Morquio A

被引:0
|
作者
Sergio Olarte-Avellaneda
Alexander Rodríguez-López
Carlos Javier Alméciga-Díaz
Luis Alejandro Barrera
机构
[1] Universidad Colegio Mayor de Cundinamarca,Clinical Bacteriology Program, School of Health Sciences
[2] Pontificia Universidad Javeriana,Proteins Expression and Purification Laboratory, Institute for the Study of Inborn Errors of Metabolism, School of Sciences
来源
Molecular Biology Reports | 2014年 / 41卷
关键词
MPS IV A; GALNS; Keratan sulfate; Chondroitin-6-sulfate; Molecular modeling; Computational molecular docking;
D O I
暂无
中图分类号
学科分类号
摘要
Mucopolysaccharidosis IV A (MPS IV A) is a lysosomal storage disease produced by the deficiency of N-acetylgalactosamine-6-sulfate sulfatase (GALNS) enzyme. Although genotype–phenotype correlations have been reported, these approaches have not enabled to establish a complete genotype–phenotype correlation, and they have not considered a ligand–enzyme interaction. In this study, we expanded the in silico evaluation of GALNS mutations by using several bioinformatics tools. Tertiary GALNS structure was modeled and used for molecular docking against galactose-6-sulfate, N-acetylgalactosamine-6-sulfate, keratan sulfate, chondroitin-6-sulfate, and the artificial substrate 4-methylumbelliferyl-β-d-galactopyranoside-6-sulfate. Furthermore, we considered the evolutionary residue conservation, change conservativeness, position within GALNS structure, and the impact of amino acid substitution on the structure and function of GALNS. Molecular docking showed that amino acids involved in ligand interaction correlated with those observed in other human sulfatases, and mutations within the active cavity reduced affinity of all evaluated ligands. Combination of several bioinformatics approaches allowed to explaine 90 % of the missense mutations affecting GALNS, and the prediction of the phenotype for another 21 missense mutations. In summary, we have shown for the first time a docking evaluation of natural and artificial ligands for human GALNS, and proposed an update in genotype–phenotype correlation for Morquio A, based on the use of multiple parameters to predict the disease severity.
引用
收藏
页码:7073 / 7088
页数:15
相关论文
共 50 条
  • [21] Characterization and pharmacokinetic study of recombinant human N-acetylgalactosamine-6-sulfate sulfatase
    Tomatsu, Shunji
    Montano, Adriana M.
    Gutierrez, Monica
    Grubb, Jeffrey H.
    Oikawa, Hirotaka
    Dung, Vu Chi
    Ohashi, Amiko
    Nishioka, Tatsuo
    Yamada, Masamichi
    Yamada, Maria
    Tosaka, Yasuhiro
    Trandafirescu, Georgeta G.
    Orii, Tadao
    MOLECULAR GENETICS AND METABOLISM, 2007, 91 (01) : 69 - 78
  • [22] Enzyme replacement therapy for Morquio A: an active recombinant N-acetylgalactosamine-6-sulfate sulfatase produced in Escherichia coli BL21
    Rodriguez, Alexander
    Espejo, Angela J.
    Hernandez, Alejandra
    Velasquez, Olga L.
    Lizaraso, Lina M.
    Cordoba, Henry A.
    Sanchez, Oscar F.
    Almeciga-Diaz, Carlos J.
    Barrera, Luis A.
    JOURNAL OF INDUSTRIAL MICROBIOLOGY & BIOTECHNOLOGY, 2010, 37 (11) : 1193 - 1201
  • [23] MORQUIO-DISEASE - ISOLATION, CHARACTERIZATION AND EXPRESSION OF FULL-LENGTH CDNA FOR HUMAN N-ACETYLGALACTOSAMINE-6-SULFATE SULFATASE
    TOMATSU, S
    FUKUDA, S
    MASUE, M
    SUKEGAWA, K
    FUKAO, T
    YAMAGISHI, A
    HORI, T
    IWATA, H
    OGAWA, T
    NAKASHIMA, Y
    HANYU, Y
    HASHIMOTO, T
    TITANI, K
    OYAMA, R
    SUZUKI, M
    YAGI, K
    HAYASHI, Y
    ORII, T
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 181 (02) : 677 - 683
  • [24] Four novel mutations in the N-acetylgalactosamine-6-sulfate sulfatase gene among Egyptian patients with Morquio A disease
    Fateen, Ekram M.
    Abd El Mawgoud, Hanan
    Eissa, Noura R.
    Ibrahim, Mona M.
    Aglan, Mona S.
    Essawi, Mona L.
    GENE, 2017, 600 : 48 - 54
  • [25] Combined adenine phosphoribosyltransferase and N-acetylgalactosamine-6-sulfate sulfatase deficiency
    Wang, L
    Ou, X
    Sebesta, I
    Vondrak, K
    Krijt, J
    Elleder, M
    Poupetova, H
    Ledvinova, J
    Zeman, J
    Simmonds, HA
    Tischfield, JA
    Sahota, A
    MOLECULAR GENETICS AND METABOLISM, 1999, 68 (01) : 78 - 85
  • [26] Molecular Analysis of Turkish Mucopolysaccharidosis IVA (Morquio A) Patients: Identification of Novel Mutations in the N-acetylgalactosamine-6-sulfate sulfatase (GALNS) Gene
    Terzioglu, Mugen
    Tokatli, Aysegul
    Coskun, Turgay
    Emre, Serap
    HUMAN MUTATION, 2002, 20 (06) : 477 - 478
  • [27] MUCOPOLYSACCHARIDOSIS TYPE-IVA - N-ACETYLGALACTOSAMINE-6-SULFATE SULFATASE EXONIC POINT MUTATIONS IN CLASSICAL MORQUIO AND MILD CASES
    FUKUDA, S
    TOMATSU, S
    MASUE, M
    SUKEGAWA, K
    IWATA, H
    OGAWA, T
    NAKASHIMA, Y
    HORI, T
    YAMAGISHI, A
    HANYU, Y
    MOROOKA, K
    KIMAN, T
    HASHIMOTO, T
    ORII, T
    JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (03): : 1049 - 1053
  • [28] LATE ONSET N-ACETYLGALACTOSAMINE-6-SULFATE SULFATASE DEFICIENCY IN 2 BROTHERS
    ORII, T
    SUKEGAWA, K
    TAGA, T
    JAPANESE JOURNAL OF HUMAN GENETICS, 1982, 27 (02): : 138 - 138
  • [29] BIOCHEMICAL HETEROGENEITY OF N-ACETYLGALACTOSAMINE-6-SULFATE SULFATASE OF NORMAL FIBROBLASTS AND OF FIBROBLASTS FROM PATIENTS WITH MORQUIO DISEASE TYPE-A
    GLOSSL, J
    KRESSE, H
    HOPPE-SEYLERS ZEITSCHRIFT FUR PHYSIOLOGISCHE CHEMIE, 1980, 361 (09): : 1286 - 1287
  • [30] Recombinant human N-acetylgalactosamine-6-sulfate sulfatase (GALNS) produced in the methylotrophic yeast Pichia pastoris
    Alexander Rodríguez-López
    Carlos J. Alméciga-Díaz
    Jhonnathan Sánchez
    Jefferson Moreno
    Laura Beltran
    Dennis Díaz
    Andrea Pardo
    Aura María Ramírez
    Angela J. Espejo-Mojica
    Luisa Pimentel
    Luis A. Barrera
    Scientific Reports, 6